259 results about "Glycated hemoglobin" patented technology

A method of determining glycated hemoglobin is provided, by which a ratio of the glycated hemoglobin in a sample can be determined accurately and easily. The ratio of glycated hemoglobin can be determined by degrading a glycated hemoglobin in a whole blood sample selectively with a protease to give a glycated hemoglobin degradation product; causing a redox reaction between a glycation site of the glycated hemoglobin degradation product and a fructosyl amino acid oxidoreductase; and determining this redox reaction. Further, as shown in FIG. 1, in a whole blood sample, there is a correlation between the ratio of the glycated hemoglobin determined by this method and an HbA1c concentration. Thus, without determining the glycated α-amino group as a characteristic structure of HbA1c, an amount of HbA1c can be determined accurately and easily from the determined ratio of the glycated hemoglobin.

Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) siabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the effects of glycated hemoglobin, and an assay method are provided. Thus, the contents of a glycated protein and glycated albumin can be more accurately determined.

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

A reaction cassette for a glycated hemoglobin meter and a measuring method thereof are provided. The reaction cassette for the glycated hemoglobin meter includes: a first zone receiving a first reagent and a blood sample; a second zone receiving a second reagent; a reaction zone in which the blood sample reacts with the first reagent, or through which the second reagent passes to react with a first blood sample mixture obtained by reacting the blood sample with the first reagent; and a measurement zone measuring an amount of total hemoglobin in the first blood sample mixture, or measuring an amount of glycated hemoglobin in a second blood sample mixture obtained by reacting the first blood sample mixture with the second reagent, wherein the blood sample, the first reagent, and the second reagent move between the reaction zone and the measurement zone according to a rotation angle of the reaction cassette when the reaction cassette is rotated. Therefore, since the reaction cassette rotates automatically, it is possible to measure the amount of glycated hemoglobin in a blood sample through simple manipulation and reduce a manufacturing time. Furthermore, since reagents are supplied to the reaction cassette from a separate reagent pack, it is possible to resolve storage and distribution problems of the reaction cassette, which occur when reagents are stored in the reaction cassette.